The promise of blood-based dementia screening has faced a critical gap: most validation studies focus on European and North American populations, leaving billions worldwide without proven diagnostic tools. This limitation becomes particularly concerning as dementia rates surge globally, yet biomarker performance can vary significantly across genetic backgrounds and environmental exposures.
A comprehensive analysis of 605 participants across multiple Latin American countries demonstrates that plasma AT(N) biomarkers can reliably distinguish Alzheimer's disease from frontotemporal lobar degeneration in genetically diverse populations. The research identified specific patterns: reduced amyloid-beta 42/40 ratios alongside elevated phosphorylated tau proteins (p-tau217 and p-tau181) in both conditions, while neurofilament light chain showed particularly pronounced increases in frontotemporal cases. Individual biomarker panels achieved diagnostic accuracy of 83% for Alzheimer's and 88% for frontotemporal dementia.
This validation carries profound implications for global dementia care, as Latin America represents one of the world's most genetically admixed populations with significant Indigenous, European, and African ancestry. The consistency across countries suggests these biomarkers may perform reliably regardless of genetic background—a crucial finding for developing universal screening protocols. When researchers combined plasma markers with neuroimaging and cognitive assessments, accuracy improved to 95% for frontotemporal dementia, approaching clinical-grade precision. The correlation between biomarker levels and specific cognitive domains also suggests potential for tracking disease progression. However, this remains a single regional study, and validation across other underrepresented populations will determine whether blood-based dementia screening can truly achieve global applicability.